ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective

Haemophilia

Volumn 20, Issue SUPPL. 6, 2014, Pages 17-26

  Oldenburg, J ^a   Austin, S K ^b   Kessler, C M ^c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

Decision analytic model; Factor VIII; Haemophilia A; Immune tolerance induction therapy; Inhibitors; Prognosis

Indexed keywords

BLOOD CLOTTING FACTOR 8; PROTHROMBIN COMPLEX; VON WILLEBRAND FACTOR; BLOOD CLOTTING INHIBITOR; COAGULATING AGENT;

CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; EARLY INTERVENTION; ECONOMIC ASPECT; FAMILY HISTORY; GERMANY; HEMOPHILIA A; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; IMMUNOLOGY;

BLOOD COAGULATION FACTOR INHIBITORS; COAGULANTS; COST-BENEFIT ANALYSIS; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; VON WILLEBRAND FACTOR;

EID: 84903212553     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12466     Document Type: Review

References (59)

1. Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years 'Bonn protocol'. Vox Sang 1996; 70(Suppl 1): 30-5.
2. Nilsson IM, Berntorp E, Zettervall O. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med 1988; 318: 947-50.
3. Freiburghaus C, Berntorp E, Ekman M, Gunnarsson M, Kjellberg B, Nilsson IM. Tolerance induction using the Malmö treatment model 1982-1995. Haemophilia 1999; 5: 32-9.
4. Mauser-Bunschoten EP, Nieuwenhuis HK, Roosendaal G, van den Berg HM. Low-dose immune tolerance induction in hemophilia A patients with inhibitors. Blood 1995; 86: 983-8.
5. Sultan Y, Rossi F, Kazatchkine MD. Recovery from anti-VIII: C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII: C autoantibodies. Proc Natl Acad Sci USA 1987; 84: 828-31.
6. Gilles JG, Desqueper B, Lenk H, Vermylen J, Saint-Remy JM. Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J Clin Invest 1996; 97: 1382-8.
7. Hausl C, Ahmad RU, Sasgary M et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106: 3415-22.
8. Miao CH, Harmeling BR, Ziegler SF et al. CD4 + FOXP3 + regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. Blood 2009; 114: 4034-44.
9. Miao CH. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 2010; 3: 469-83.
10. Mariani G, Kroner B. Immune Tolerance Study Group (ITSG). Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001; 86: 1186-93.
11. Hay CR, DiMichele DM; on behalf of the International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
12. Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate. Haemophilia 2014; 20: 83-91.
13. Di Michele DM, Hoots WK, Pipe SW, Rivard GE, Santagostino E. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1-22.
14. Gringeri A, Musso R, Bernasconi S et al. Immunotolerance induction (ITI) with high-purity FVIII/VWF concentrates in inhibitors patients with a high risk of a poor response to ITI: a prospective surveillance. J Thromb Haemost 2005; 3(Suppl. 1): A207.
15. Astermark J, Morado M, Rocino A et al. Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors. Haemophilia 2006; 12: 363-71.
16. Blanchette VS, Shapiro AD, Liesner RJ et al. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost 2008; 6: 1319-26.
17. Collins PW, Chalmers E, Hart DP et al. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization. Br J Haematol 2013; 160: 153-70.
18. Björkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.
19. UKHCDO Annual Report 2012. Available at http://www.ukhcdo.org/docs/AnnualReports/2012/1UK%20National%20Haemophilia%20Database%20Bleeding%20Disorder%20Statistics%202011-2012%20for%20website.pdf. Accessed October 8, 2013.
20. Lenk H; ITT Study Group. The German Registry of immune tolerance treatment in hemophilia-1999 update. Haematologica 2000; 85 (10 Suppl): 45-7.
21. DiMichele DM, Kroner BL; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. Thromb Haemost 2002; 87: 52-7.
22. Ettingshausen CE, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coagul Fibrinolysis 2005; 16(Suppl 1): S27-31.
23. Auerswald G, Spranger T, Brackmann HH. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients. Haematologica 2003; 88(Suppl 9): 21-5.
24. Gringeri A, Musso R, Mazzucconi MG et al. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia 2007; 13: 373-9.
25. Kurth M, Puetz J, Kouides P et al. The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience. J Thromb Haemost 2011; 9: 2229-34.
26. ®) in 14 patients with severe haemophilia A. Haemophilia 2011; 17: e837-40.
27. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-28.
28. Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile. Haemophilia 2008; 14: 295-302.
29. Kurth MA, DiMichele D, Sexauer C et al. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia 2008; 14: 50-5.
30. Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica 2005; 90: 1288-90.
31. Kreuz W, Escuriola-Ettingshausen C, Auerswald G et al. Immune tolerance induction (ITI) in haemophilia A with inhibitors: the choice of concentrate affecting success. Haematologica 2001; 86(Suppl. 4): 16-20.
32. Ettingshausen CE, Kreuz W. The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture? Haemophilia 2013; 19(Suppl 1): 12-7.
33. Mathias M, Khair K, Liesner R. Immune tolerance with plasma derived FVIII/VWD concentrate in boys with sever haemophilia A and resistant inhibitors. Poster presentation at the 16th Congress of the European Haematology Association, London, 9-12 June 2011.
34. Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007; 13(Suppl 5): 73-7.
35. Observational Immune Tolerance Induction (ObsITI) research program. Available at http://www.obsiti.com. Accessed October 10, 2013.
36. ® in the ObsITI study [PO066]. Haemophilia 2013; 19 (Suppl 2): 48.
37. Hay CRM, Ludlam CA, Colvin BT et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost 1998; 79: 762-6.
38. Franchini M, Mengoli C, Lippi G et al. Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. Haemophilia 2008; 14: 903-12.
39. Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78: 256-60.
40. van Helden PM, Kaijen PH, Mauser-Bunschoten EP, Fischer K, van den Berg HM, Voorberg J. Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A. Haemophilia 2010; 16: 892-901.
41. Tagariello G, Zanotto D, Radossi P, Sartori R, Belvini D, Salviato R. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates. Am J Hematol 2007; 82: 460-2.
42. Ghio M, Contini P, Ottonello L et al. Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro. Thromb Haemost 2003; 89: 365-73.
43. Kempton CL, White GC 2nd. How we treat a hemophilia A patient with a factor VIII inhibitor. Haemophilia 2009; 113: 11-7.
44. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
45. Fischer K, Pouw ME, Lewandowski D, Janssen MP, van den Berg HM, van Hout BA. A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A. Haematologica 2011; 96: 738-43.
46. Kulkarni R, Soucie JM, Lusher J et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention's (CDC) Universal Data Collection (UDC) project. Haemophilia 2009; 15: 1281-90.
47. Ogden CL, Fryar CD, Carroll MD, Flegal KM. Mean body weight, height, and body mass index, United States 1960-2002. Advance data from vital and health statistics; No 347. Hyattsville, Maryland: National Center for Health Statistics. 2004. Available at http://www.cdc.gov/nchs/data/ad/ad347.pdf. Accessed October 9, 2013.
48. Astermark J, Donfield SM, DiMichele DM et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007; 109: 546-51.
49. Leissinger C, Gringeri A, Antmen B et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. New Engl J Med 2011; 365: 1684-92.
50. Srivastava A, Brewer AK, Mauser-Bunschoten EP et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
51. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
52. Soucie JM, Nuss R, Evatt B et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000; 96: 437-42.
53. Walsh C, Miller C, Soucie M. Increased mortality risk in US hemophilia inhibitor patients [Abstract PA 4.13-5]. Presented at the 24th Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, Netherlands, 29 June-4 July 2013.
54. FFF Enterprises Open Market Pricing. Available at http://fffenterprises.com/Products/OpenMarketPricing.aspx. Accessed July 12, 2013.
55. Overview of the Nationwide Inpatients Sample. Healthcare Cost and Utilization Project (HCUP) 2010. Available at http://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed October 9, 2013.
56. RBRVS Schedule 2013. Available at http://www.rbrvs.net/. Accessed October 9, 2013.
57. Boulanger L, Hauch O, Friedman M et al. Warfarin exposure and the risk of thromboembolic and major bleeding events among Medicaid patients with atrial fibrillation. Ann Pharmacother 2006; 40: 1024-9.
58. Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
59. Noone D, O'Mahony B, van Dijk JP, Prihodova L. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013; 19: 44-50.